For instance, one study established a co-culture system using autologous HBV-positive hepatocellular carcinoma organoids with CD39+ HBV-CAR T cells or CD39+ personalized tumor-reactive CD8+ T cells to assess their anticancer efficacy [56]. This evidence concerns the gene ENTPD1 and hepatocellular carcinoma.